Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HbF Inducers (Thalidomide and Hydroxyurea) in Beta Thalassemia
NCT07673302Recruiting
- Sponsor
- Riphah International University
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Open-label trial of thalidomide and hydroxyurea in beta thalassemia (2 arms), sponsored by Riphah International University. Primary endpoints: Improvement in the hemoglobin level at 6 months and Decrease in transfusion requirement at 6 months. Started Jun 2026; status: recruiting.
02
Drugs
thalidomidehydroxyurea
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT07673302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07673302.